Compare WS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | NEO |
|---|---|---|
| Founded | 1955 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2023 | 2008 |
| Metric | WS | NEO |
|---|---|---|
| Price | $39.72 | $16.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $21.85 |
| AVG Volume (30 Days) | 437.3K | ★ 2.3M |
| Earning Date | 10-06-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,443,800,000.00 | N/A |
| Revenue This Year | $11.55 | $10.71 |
| Revenue Next Year | $0.38 | $9.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.33 | N/A |
| 52 Week Low | $27.22 | $7.07 |
| 52 Week High | $49.17 | $20.15 |
| Indicator | WS | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 43.04 |
| Support Level | $38.01 | $15.57 |
| Resistance Level | $39.42 | $16.92 |
| Average True Range (ATR) | 1.92 | 0.98 |
| MACD | 0.34 | -0.18 |
| Stochastic Oscillator | 80.29 | 23.00 |
Worthington Steel Inc is a value-added metals processors with the ability to provide a diversified products and services that span a variety of end markets. It is a value-added processor of carbon flat-rolled steel and a producer of laser welded solutions and electrical steel laminations. It is one of the independent intermediate processors of carbon flat-rolled steel in the U.S. It occupy a niche in the steel industry by focusing on products requiring exact specifications. The company has one operating and reportable segment. It has presence in United States, Canada, Mexico, and Rest of world. The company has majority of sales from United States.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.